Clinical trialEarly Phase 1Withdrawn
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
A Pilot Proof of Mechanism Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPPs), in Patients With Pancreatic Cancer
- Outcome
- Stopped earlyNo longer relevant to field (Other)
- Phase
- Early Phase 1
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 15 October 2019
- Planned end
- 6 December 2021
- Enrollment
- 0 participants
- Sites
- 2
- Primary outcomes
- To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action.
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 11 August 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
This is a Phase 0 or "window of opportunity" study where paired specimen analysis, taken before and after drug exposure, will permit the evaluation of target modulation and assessment of immune effector cell infiltration into the tumor and the generation of relevant immune cytokines. In this study, BXCL701 will be administered at a dose of 0.3 mg, twice daily for a total daily dose of 0.6mg (the previously defined maximum tolerated dose \[MTD\] of the drug), to all patients for a short period of 14 days. This study is designed to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.